Filtered By:
Condition: Congestive Heart Failure
Drug: Insulin

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 179 results found since Jan 2013.

Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi ‐database, non‐interventional post‐authorization safety study
Abstract This non‐interventional, multi‐database, analytical cohort study assessed the cardiovascular (CV) safety of vildagliptin vs. other non‐insulin antidiabetic drugs (NIADs) using real‐world data from five European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regressio...
Source: Diabetes, Obesity and Metabolism - March 24, 2017 Category: Endocrinology Authors: R. Williams, F. de Vries, W. Kothny, C. Serban, S. Lopez ‐Leon, C. Chu, R. Schlienger Tags: BRIEF REPORT Source Type: research

Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Testosterone and cardiac mass and function in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC)
ConclusionsAmong men with type 1 diabetes, higher total testosterone was associated with higher LV mass and volume but not with function. The clinical significance of this association remains to be established.This article is protected by copyright. All rights reserved.
Source: Clinical Endocrinology - December 7, 2015 Category: Endocrinology Authors: Catherine Kim, Ionut Bebu, Barbara Braffett, Patricia A. Cleary, Valerie Arends, Michael Steffes, Hunter Wessells, Trevor Orchard, Aruna V. Sarma, Tags: Original Article Source Type: research

Safety and efficacy of glucose-insulin-potassium treatment in coronary artery bypass graft surgery and percutaneous coronary intervention
The purpose of this meta-analysis was to evaluate protective effects of glucose–insulin–potassium (GIK) on outcomes after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). We systematically searched Medline/Pubmed, Elsevier, Embase, Web of Knowledge and Google Scholar. A total of 1206 studies were retrieved during the extensive literature search of all major databases; however, 38 trials reporting the end-point of interest were selected. We performed a pooled analysis of outcomes following PCI: incidence of cardiac arrest [odds ratio (OR) of 0.91; 95% confidence interval (CI): ...
Source: Interactive CardioVascular and Thoracic Surgery - October 19, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Ali-Hassan-Sayegh, S., Mirhosseini, S. J., Zeriouh, M., Dehghan, A. M., Shahidzadeh, A., Karimi-Bondarabadi, A. A., Sabashnikov, A., Popov, A.-F. Tags: Congestive Heart Failure Adult Cardiac Source Type: research

Age-Specific Performance of the Revised Cardiac Risk Index for Predicting Cardiovascular Risk in Elective Noncardiac Surgery Original Articles
Conclusions— In a nationwide unselected cohort, the performance of the RCRI was similar to that of the original cohort. Having ≥1 risk factor was of moderate sensitivity, but high negative predictive value for all ages.
Source: Circulation: Cardiovascular Quality and Outcomes - January 20, 2015 Category: Cardiology Authors: Andersson, C., Wissenberg, M., Jorgensen, M. E., Hlatky, M. A., Merie, C., Jensen, P. F., Gislason, G. H., Kober, L., Torp-Pedersen, C. Tags: Other diagnostic testing Original Articles Source Type: research

Metformin associated with better cardiovascular outcomes than other glycaemic therapies
Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interv...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Bloomgarden, Z. T. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Diet, Obesity (nutrition), Ischaemic heart disease, Diabetes, Health education, Smoking Therapeutics Source Type: research

Study may bust myth of 'fat and fit' healthy obesity
Conclusion This meta-analysis provides further evidence about the known risk factors for cardiovascular disease and mortality. What this study adds is the indication that people who are metabolically unhealthy regardless of their weight are at increased risk. However, interestingly, no increase in risk was seen for the category of people who are metabolically healthy though overweight. A strength of this meta-analysis is the large sample size. However, the results should be interpreted with caution as: The studies did not use the same criteria for assessing metabolic status. The studies did not use the same criteri...
Source: NHS News Feed - December 4, 2013 Category: Consumer Health News Tags: Food/diet Lifestyle/exercise Obesity Source Type: news

Good Fat, Bad Fat The Increasingly Complex Interplay of Adipose Tissue and the Cardiovascular System ∗
Obesity is present in more than 30% of adults in the United States and is a known risk factor for a variety of cardiovascular problems, including coronary artery disease, atrial fibrillation, congestive heart failure, and stroke (1). Obesity is considered to be present when there is an excess mass of adipose tissue in the body. There is now widespread acceptance of the notion that regional fat stores might have specific local or systemic effects. The best-known example of a local fat depot with a specific effect is the case of excess fat within the abdominal cavity, which seems to contribute to insulin resistance, raised b...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - July 1, 2013 Category: Cardiology Source Type: research

Good Fat, Bad Fat: The Increasingly Complex Interplay of Adipose Tissue and the Cardiovascular System∗
Obesity is present in more than 30% of adults in the United States and is a known risk factor for a variety of cardiovascular problems, including coronary artery disease, atrial fibrillation, congestive heart failure, and stroke . Obesity is considered to be present when there is an excess mass of adipose tissue in the body. There is now widespread acceptance of the notion that regional fat stores might have specific local or systemic effects. The best-known example of a local fat depot with a specific effect is the case of excess fat within the abdominal cavity, which seems to contribute to insulin resistance, raised bloo...
Source: Journal of the American College of Cardiology - May 13, 2013 Category: Cardiology Authors: Sheldon E. Litwin Tags: Cardiometabolic Risk: Editorial Comment Source Type: research

Impact of Adding Aspirin to Beta-Blocker and Statin in High-Risk Patients Undergoing Major Vascular Surgery
In this study we evaluated the benefits of adding aspirin (A) to BB and S (ABBS), with/without angiotensin-converting enzyme inhibitor (ACE-I) on postoperative outcome in high-risk patients undergoing major vascular surgery.Methods: Analysis of consecutive patients undergoing elective vascular surgery at the University of Michigan Cardiovascular Center was performed. Univariate and multivariate analyses were done using cardiac risk index [Revised Cardiac Risk Index (RCRI), coronary artery disease (CAD), insulin-dependent diabetes mellitus (IDDM), cerebral vascular disease, renal dysfunction, congestive heart failure, and m...
Source: Annals of Vascular Surgery - March 25, 2013 Category: Surgery Authors: Wei C. Lau, James B. Froehlich, Elizabeth S. Jewell, Daniel G. Montgomery, Kristina M. Eng, Theresa A. Shields, Peter K. Henke, Kim A. Eagle Tags: Basic Data Underlying Clinical Decision-Making in Endovascular Therapy Source Type: research

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
Conclusion The 1-year risk for death, reinfarction, or stroke did not relate to glycaemic variability in T2DM patients with AMI treated with insulin infusion.
Source: European Heart Journal - February 1, 2013 Category: Cardiology Authors: Mellbin, L. G., Malmberg, K., Ryden, L., Wedel, H., Vestberg, D., Lind, M. Tags: Coronary artery disease Source Type: research